What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?

Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug Administration-approved drugs could provide significant revenue growth in the coming years. Sales of its bad cholesterol-lowering drug Praluent are starting to pick up, and the eczema drug Dupixent and rheumatoid arthritis drug Kevzara have recently launched.

In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss the opportunities -- and the risks -- associated with Regeneron's newest products.

A full transcript follows the video.

Source: Fool.com